Conference Proceedings

HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2 breast cancer

Sara Hurvitz, Linda Vahdat, Nadia Harbeck, Antonio C Wolff, Sara M Tolaney, Sherene Loi, Norikazu Masuda, Joyce O'Shaughnessy, Cassie Dong, Luke Walker, Evelyn Rustia, Virginia F Borges

CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2021